Last reviewed · How we verify
NCT07394296: MIDRELAY
Study of the Prevalence of Midline Replacements and the Reasons for These Replacements
trial in Veinous Access in 984 participants. Currently enrolling.
5 January 2027
Quick facts
| Lead sponsor | Centre Hospitalier de Valenciennes |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 984 |
| Start date | 2 December 2025 |
| Primary completion | 5 January 2027 |
| Estimated completion | 5 January 2027 |
| Sites | 1 location across France |
Conditions studied
- Veinous Access — all drugs for Veinous Access →
- Midline — all drugs for Midline →
- Veinous Capital — all drugs for Veinous Capital →
Sponsor
Centre Hospitalier de Valenciennes
Who can join
18 and older, any sex, with Veinous Access or Midline. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Venous access management plays a key role in patient care and preserving their venous capital. The so-called "conventional" peripheral venous catheter is the most common venous access device, but it is associated with a high rate of complications, particularly in cases of prolonged use or poor venous capital. Recommendations, such as those from MAGIC or SF2H, advocate their use when the intended duration of use is 5 days or less. For longer periods or in cases of difficult access, so-called "central" devices such as PICC lines or central venous catheters are used, although they present specific risks such as CLASBI or deep vein thrombosis. In intermediate situations, the midline, a peripheral venous access device, is a relevant alternative, particularly for non-venotoxic intravenous treatments lasting more than 5 days. Although it is theoretically associated with fewer infections and complications than the PICCline, its complication rate and actual duration of use vary widely in the literature. The MAGIC recommendations suggest using them for periods of 14 days or less. The widespread use of midlines in healthcare facilities, and in particular the creation of vascular access units, has given rise to issues shared between centers, notably the replacement rate of these devices. The study therefore aims to determine the replacement and early removal rates for midlines, the circumstances in which they are replaced, and toassess the relevance of the 28-day limit in the choice of device, in order to improve practices and optimize the practitioner's initial decision.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07394296
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Centre Hospitalier de Valenciennes trials
Trials by the same sponsor.
- NCT07054528 — Multicentre Real-life Data Collection Study With CareMin650™ in the Prevention and Treatment of Oral Mucositis and Radio · active not recruiting
- NCT06278558 — Psychological Factors Influencing Cancer Post-traumatic Growth · NA · recruiting
- NCT06589908 — Evaluation of the Use of RELAX Glasses on Anxiety of Patients Undergoing Dental Extraction > 2 Teeth, Under Local Anesth · NA · completed
- NCT06436118 — Evaluation of the Use of the RELAX® Glasses on the Anxiety of Patients Undergoing Emergency Hand Surgery Under Locoregio · NA · completed
- NCT06227663 — Impact on Anxiety of a Digital Application for Children Undergoing Scheduled Ambulatory Surgery · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07394296 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier de Valenciennes
- Last refreshed: 10 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07394296.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing